Optimi Health Secures US$100M Equity Line of Credit with Seven Knots
OPTH sits 50% above its 52-week low of $3.12 on light trading volume (0.2× avg).
Summary
Optimi Health established a US$100 million equity line of credit with Seven Knots, LLC, providing flexible access to capital through share sales at a 3% discount, along with convertible notes totaling up to US$2 million.
Key Events · Financing and Capital Events · OPTH
-
US$100M Equity Line of Credit
Optimi Health entered into a common shares purchase agreement with Seven Knots, LLC, establishing an equity line of credit under which the company may sell up to US$100 million of common shares from time to time at its discretion.
-
Pricing and Draw Terms
Each draw is priced at 97% of the lower of the lowest sale price or VWAP during the purchase period, with a maximum draw of US$2 million. Purchases terminate if the share price falls below 85% of the prior day's closing price.
-
Convertible Commitment Notes
As consideration, Optimi issued a US$1.5 million unsecured, non-interest-bearing convertible note, with a potential additional US$500,000 note if ELOC draws reach US$7 million. Notes mature in 24 months and convert at 95% of the 20-day VWAP with a US$3.00 floor.
-
Placement Agent Fee
Joseph Gunnar & Co. LLC is acting as exclusive placement agent and will receive a fee equal to 3% of gross proceeds from share purchases under the ELOC.
Analysis · OPTH · Life Sciences
Optimi Health has entered into a US$100 million equity line of credit with Seven Knots, LLC, giving the company the right, but not the obligation, to sell shares over time. The facility is priced at a 3% discount to the lower of the lowest sale price or VWAP during the purchase period, with a maximum draw of US$2 million per purchase. As consideration, Optimi issued a US$1.5 million convertible note, with a potential additional US$500,000 note if draws reach US$7 million. The notes convert at 95% of the 20-day VWAP with a US$3.00 floor, and are prepayable at par. This financing provides significant potential capital but carries dilution risk and a convertible note overhang. The company's stock price of $4.6672 is above the $3.00 conversion floor, so the notes are currently in-the-money for conversion.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1012 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPTH was trading at $4.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.4M. The 52-week trading range was $3.12 to $8.84. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.